Navigation Links
New clinical trial to examine medication to treat social withdrawal in Fragile X and autism
Date:7/20/2011

(CHICAGO) Children and adults with social withdrawal due to Fragile X syndrome, the most common cause of inherited intellectual disability and the most common known single gene cause of autism, may benefit from an experimental drug under study by pediatric neurologists at Rush Children's Hospital at Rush University Medical Center.

Rush is the only site in Illinois and one of 21 hospitals in the U.S. participating in the trial for Fragile X.

Fragile X syndrome is a neurodevelopmental disorder characterized by impaired social function, cognition and speech, as well as attention deficits and anxiety.

People with Fragile X, autism or autism spectrum disorders often display social impairment including social withdrawal and anxiety and have difficulty communicating and interacting with others. Although there are behavioral and psychological interventions, there are no approved medications for the treatment of social or communication difficulties in Fragile X, autism and autism spectrum disorders.

"The condition can be severely debilitating and this medication has the potential to play a much needed role in improving the core symptoms of fragile X syndrome and helping patients and their families achieve an improved quality of life," said Dr. Elizabeth Berry-Kravis, pediatric neurologist at Rush and principal investigator of the study.

The study is sponsored by Seaside Therapeutics, Inc, and will test the efficacy, safety and tolerability of the drug called STX209 (arbaclofen).

Racemic baclofen (mixture of arbaclofen and esbaclofen) is approved by the FDA to treat spasticity and stiff muscles due to cerebral palsy or other forms of brain or spinal cord injury, but arbaclofen, the more active form of baclofen, is not FDA approved.

"There is some evidence that the medication may help with social behaviors in people with developmental disabilities," said Berry-Kravis, who is a professor of pediatrics, neurology and biochemistry at Rush University.

Participants in the randomized, double-blind, placebo controlled phase III trial will be randomized to receive either the study drug, STX209, or a placebo. The clinical trial will include screening, treatment, withdrawal of medication, and a follow-up period. Subjects who complete the study may be eligible to enroll in a subsequent open-label study in which all subjects are treated with STX209.

STX209 has been studied in a previous small placebo-controlled trial in children and adults with fragile X syndrome and showed evidence of benefit for social withdrawal.

"Previous research has found that from one-quarter to one-half of people with fragile X have autism spectrum disorders," said Berry-Kravis.

"This trial is exciting, because it represents the culmination of 20 years work in fragile X research since discovery of the fragile X gene in 1991," said Kravis. "We're not expecting this to cure fragile X or autism, but it's a very important step in the development of new treatments."


'/>"/>

Contact: Deb Song
deb_song@rush.edu
312-942-0588
Rush University Medical Center
Source:Eurekalert

Related medicine news :

1. PACS improves radiologists use of clinical decision support systems
2. Wake Forest Baptist conducts clinical study for insomnia using new technology
3. Damon Runyon Cancer Research Foundation awards $3.45 million to 9 top young clinical investigators
4. Neuralstem updates clinical trial progress
5. Universal flu vaccine clinical trials show promise
6. Pioneering stem cell bandage receives approval for clinical trial
7. NIH grant for the move toward clinical trials targeting the lysosomal storage disease MPSIIIB
8. Clinical trials for new Alzheimers disease treatment to be awarded European Commission €6m funding
9. Dubai to host largest clinical bone meeting in the Middle East and Africa region
10. Top 5 list helps primary care doctors make wiser clinical decisions
11. Researchers examine procedure utilization trends in patients with clinically localized renal masses
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/5/2016)... ... December 05, 2016 , ... ... and relationship-marketing firm, announced today that nominations will be accepted from December ... (ISE®) Central Awards. , Awards include the Information Security Executive® of the ...
(Date:12/5/2016)... ... December 05, 2016 , ... Physicians Education Resource®, LLC ... Congress on Hematologic Malignancies®: Focus on Leukemias, Lymphomas, and Myeloma, on February 24, ... honored to have Amy E. Herman present at this year’s conference, her unprecedented ...
(Date:12/5/2016)... ... December 05, 2016 , ... U.S. Apple Association (USApple) ... part of the second annual Apples for Education: Buy an Apple, Help a ... providing healthy food for students to take home to their families; solar technology to ...
(Date:12/5/2016)... (PRWEB) , ... December 05, 2016 , ... ... teaming up on new songs with prolific Songwriter-Producer Corey “Chorus” Gibson who has ... Rowland, Ciara, Brandy…just to name a few.     https://twitter.com/coreychorus , The sessions ...
(Date:12/5/2016)... ... December 05, 2016 , ... ... way to ensure moisture measurements are consistently correct. However, regular performance testing ... Now, METTLER TOLEDO offers a solution: SmartCal™ . This innovative test ...
Breaking Medicine News(10 mins):
(Date:12/5/2016)... LAKE, N.J. , Dec. 5, 2016 ... perampanel presented at the 2016 Annual Meeting of the ... as FYCOMPA® CIII, is indicated as an adjunctive therapy ... or without secondarily generalized seizures and primary generalized tonic-clonic ... years of age and older. Please see Important Safety ...
(Date:12/5/2016)... , December 5, 2016 PharmaBoardroom today releases ... . ... This report offers companies, investors, policymakers, and stakeholders crucial insight ... of Europe , home to some of the world,s ... pharmaceutical companies in Novartis and Roche, and with a number one ranking ...
(Date:12/4/2016)... 3, 2016 Johnson & Weaver, LLP announces that ... of Zimmer Biomet Holdings, Inc. (NYSE: ZBH ) ... 31, 2016 (the "Class Period"). Zimmer Biomet provides ... orthopaedic reconstructive products, such as knee and hip reconstructive products. ... , , ...
Breaking Medicine Technology: